Display options
Cite
Zhai M, Zhang D, Long J, et al. The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the Global Burden of Disease Study. Cancer Med. 2021;10(13):4542-4554doi: 10.1002/cam4.3970.
Zhai, M., Zhang, D., Long, J., Gong, Y., Ye, F., Liu, S., & Li, Y. (2021). The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the Global Burden of Disease Study. Cancer medicine, 10(13), 4542-4554. https://doi.org/10.1002/cam4.3970
Zhai, Mimi, et al. "The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the Global Burden of Disease Study." Cancer medicine vol. 10,13 (2021): 4542-4554. doi: https://doi.org/10.1002/cam4.3970
Zhai M, Zhang D, Long J, Gong Y, Ye F, Liu S, Li Y. The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the Global Burden of Disease Study. Cancer Med. 2021 Jul;10(13):4542-4554. doi: 10.1002/cam4.3970. Epub 2021 May 18. PMID: 34002931; PMCID: PMC8267141.
Copy Download .nbib Format: NLM
Share it on

Cancer Med. 2021 Jul;10(13):4542-4554. doi: 10.1002/cam4.3970. Epub 2021 May 18.

The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the Global Burden of Disease Study.

Cancer medicine

Mimi Zhai, Dan Zhang, Jianhai Long, Yi Gong, Fei Ye, Sushun Liu, Yamin Li

Affiliations

  1. Xiangya Nursing School, Central South University, Changsha, Hunan, China.
  2. Clinical Nursing Teaching and Research Section, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  3. Department of Respiratory, Beijing Tiantan Hospital, Capital Medicine University, Beijing, China.
  4. Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

PMID: 34002931 PMCID: PMC8267141 DOI: 10.1002/cam4.3970

Abstract

BACKGROUND: Thyroid cancer is a growing threat to human health. Few studies have explored trends of thyroid cancer and relationships with social development factors. In this study, we explored the trend and relationship based on GBD.

METHODS: By using GBD study, we obtained detailed data of thyroid cancer. Incidence, mortality and DALY were used to assess epidemiological characteristics. ASR and EAPC were used to estimate the trend.

RESULTS: Globally, the incidence significantly increased from 1990 to 2017, especially in high-income regions. Males and middle SDI region demonstrated a higher increase of age-standardized incidence rates. Unlike incidence trend, mortality trend showed a minor increase, and even showed a decreasing trend in some regions such as Eastern Sub-Saharan Africa. Additionally, the DALY trend also demonstrated a slightly increase with an EAPC of 0.77 (95% CI 0.73-0.81). More significant increase of DALY was found in males, middle SDI region and high-income Asia Pacific. The incidence of thyroid cancer peaked in middle-aged people, while the mortality and DALY peaked in elder-aged. Moreover, the proportion of thyroid cancer deaths contributable to high BMI was highest in developed countries and middle-aged people.

CONCLUSIONS: Thyroid cancer is a public health problem worldwide. Over-diagnosis might be partly responsible for its rising trend. It remains us to revise the guidelines to avoid unnecessary burdens. Moreover, we should pay attention to the risk factors of thyroid cancer. More targeted measures should be formulated to improve potential environmental and lifestyle-related factors which might contribute to rising trend of thyroid cancer.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Keywords: ASR; EAPC; GBD study; risk factor; thyroid cancer

References

  1. CMAJ. 2007 Nov 20;177(11):1357-61 - PubMed
  2. Asia Pac J Public Health. 2015 Mar;27(2):NP223-9 - PubMed
  3. N Engl J Med. 2014 Nov 6;371(19):1765-7 - PubMed
  4. Obes Rev. 2015 Dec;16(12):1042-54 - PubMed
  5. Asian Pac J Cancer Prev. 2015;16(17):7743-8 - PubMed
  6. Thyroid. 2016 Feb;26(2):306-18 - PubMed
  7. Nat Rev Endocrinol. 2016 Nov;12(11):646-653 - PubMed
  8. Surgery. 2014 Nov;156(5):1145-52 - PubMed
  9. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  10. Clin Endocrinol (Oxf). 2016 Feb;84(2):257-264 - PubMed
  11. Science. 2014 Oct 10;346(6206):229-34 - PubMed
  12. Cancer Causes Control. 2009 Feb;20(1):75-86 - PubMed
  13. Cancer. 2017 Feb 1;123(3):372-381 - PubMed
  14. JAMA. 2006 May 10;295(18):2164-7 - PubMed
  15. Cancer Epidemiol. 2013 Aug;37(4):353-9 - PubMed
  16. JAMA Oncol. 2018 Nov 1;4(11):1553-1568 - PubMed
  17. JAMA. 2017 May 9;317(18):1882-1887 - PubMed
  18. JAMA Otolaryngol Head Neck Surg. 2016 Jul 1;142(7):709-11 - PubMed
  19. Lancet. 2014 Aug 30;384(9945):766-81 - PubMed
  20. JAMA Oncol. 2019 Dec 1;5(12):1749-1768 - PubMed
  21. Endocrinology. 2013 Aug;154(8):2936-47 - PubMed
  22. Nat Rev Endocrinol. 2020 Nov;16(11):617-618 - PubMed
  23. Ann Surg Oncol. 2013 Aug;20(8):2746-53 - PubMed
  24. Thyroid. 2016 Nov;26(11):1535-1540 - PubMed
  25. Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):405-8 - PubMed
  26. Eur J Clin Invest. 2009 Aug;39(8):699-706 - PubMed
  27. JAMA Oncol. 2017 Apr 1;3(4):524-548 - PubMed
  28. J Hepatol. 2019 Apr;70(4):674-683 - PubMed
  29. Thyroid. 2014 Jan;24(1):3-6 - PubMed
  30. JAMA Netw Open. 2020 Jun 1;3(6):e208759 - PubMed
  31. Thyroid. 2014 Jan;24(1):27-34 - PubMed

Publication Types

Grant support